Findings from Shiraz University of Medical Sciences Has Provided New Data on Non-Alcoholic Fatty Liver Disease (Treatment Options for Nonalcoholic Fatty Liver Disease: a Double-blinded Randomized Placebo-controlled Trial)
Clinical Trials Daily
2019 JUN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Investigators publish new report on Liver Diseases and Conditions - Non-Alcoholic Fatty Liver Disease. According to news originating from Shiraz, Iran, by NewsRx correspondents, research stated, “Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation. Cardiovascular disease is the main cause of death in these patients.”
Financial support for this research came from Shiraz University of Medical Sciences.
Our news journalists obtained a quote from the research from the Shiraz University of Medical Sciences, “There is no Food and Drug Association-approved medication for NAFLD patients. We aimed to provide more robust evidence on the use of medications that are inexpensive and available, namely, metformin, silymarin, pioglitazone, and vitamin E, for treating NAFLD. We conducted a randomized double-blinded, placebo-controlled trial on 150 consecutive patients with NAFLD who were assigned to five groups: lifestyle plus placebo, metformin 500 mg/day, silymarin 140 mg/day, pioglithasone 15 mg/day, and vitamin E 400 IU/day, all for 3 months. Anthropometric and biochemical variables were measured at baseline and 3 months later. The mean age of the patients was 47.0 +/- 9.1 (range: 18-65) years and the sex distribution was 73 (48.7%) women and 77 (51.3%) men. Patients in all groups showed a significant improvement in anthropometric parameters such as waist circumference and BMI. There was no statistically significant difference in alanine transaminase and aspartate transaminase in the control group after treatment (P=0.51, 0.18, respectively); however, both liver enzymes decreased significantly in the other groups.”
According to the news editors, the research concluded: “This randomized double-blinded placebo-controlled clinical trial suggested a significant benefit of silymarin, pioglitazone, and vitamin E in improving liver aminotransferases in patients with NAFLD after only 3 months, without exerting any specific side effects.”
For more information on this research see: Treatment Options for Nonalcoholic Fatty Liver Disease: a Double-blinded Randomized Placebo-controlled Trial. European Journal of Gastroenterology & Hepatology, 2019;31(5):613-617. European Journal of Gastroenterology & Hepatology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; European Journal of Gastroenterology & Hepatology - http://journals.lww.com/eurojgh/pages/default.aspx)
The news correspondents report that additional information may be obtained from V. Mohammadkarimi, Shiraz University of Medical Sciences, Dept. of Internal Medicine, Shiraz 7187914678, Iran. Additional authors for this research include A. Anushiravani, N. Haddadi and M. Pourfarmanbar.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/MEG.0000000000001369. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)